Bangalore, May 13: OneSource Specialty Pharma Limited, announced its consolidated financial results for the fourth quarter and full year ended March 31, 2026, reporting a strong recovery in Q4 supported by broad-based business growth and commercial launches of semaglutide products in India.
The company reported strong quarter-on-quarter revenue growth in Q4 FY26 compared to Q3 FY26. The performance was driven by growth across all major service offerings, supported by India semaglutide commercial launches.
EBITDA for the quarter expanded more than 5x sequentially, while EBITDA margins improved significantly, driven by operating leverage on higher Contract Services and Analytics (CSA) revenues during the quarter.
Adjusted Profit After Tax (PAT) also improved from a loss in the previous quarter to a profit in Q4 FY26, alongside a positive improvement in adjusted Earnings Per Share (EPS).
For the full financial year FY26, the company reported stable operational performance across its key business segments.
Reaffirming its long-term growth outlook, OneSource Specialty Pharma reiterated its FY28 guidance of achieving approximately $400 million in revenue with EBITDA margins of around 40%.
Commenting on the performance, Neeraj Sharma, CEO & Managing Director of OneSource Specialty Pharma Limited, said:
“We saw a strong recovery in Q4 driven by broad-based business performance. The quarter was marked by successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses. With the recent back-to-back semaglutide approvals in Canada and continued expansion of our biologics pipeline, we are well positioned to sustain growth momentum into FY27.”
The company highlighted that continued expansion in its biologics pipeline, recent approvals in Canada, and momentum across injectable and soft-gelatin segments are expected to further support growth in the coming quarters.
Adjusted PAT and Adjusted EPS exclude exceptional items and scheme-related intangible amortisation.